Biohaven Ltd. (BHVN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.14B; Additional Paid in CapitalUSD $220.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.38M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.13B; Additional Paid in CapitalUSD $203.36M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.30M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.93B; Additional Paid in CapitalUSD $193.98M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.35M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.74B; Additional Paid in CapitalUSD $178.04M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $36.00K.
Biohaven Ltd. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $2.14B | $220.37M | $5.38M | $-2.35B | $12.22M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $2.13B | $203.36M | $8.30M | $-2.22B | $129.50M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $1.93B | $193.98M | $8.35M | $-2.08B | $52.07M | 12 month · $112.36M | (m) | (m) |
| 2025-09-30 | $0.00 | $1.74B | $178.04M | $36.00K | $-1.94B | $-17.16M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $1.74B | $157.02M | $-3.00K | $-1.77B | $134.59M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $1.69B | $137.47M | $73.00K | $-1.57B | $259.50M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $1.66B | $112.37M | $79.00K | $-1.35B | $423.44M | 12 month · $71.96M | 12 month · $3.34M | (m) |
| 2024-09-30 | $0.00 | $1.38B | $93.04M | $140.00K | $-1.16B | $316.01M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $1.30B | $83.83M | $-78.00K | $-998.57M | $383.74M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $910.96M | $69.39M | $-106.00K | $-678.80M | $301.45M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $887.53M | $39.80M | $-65.00K | $-499.29M | $427.98M | 12 month · $28.79M | (m) | (m) |
| 2023-09-30 | $0.00 | $618.76M | $25.62M | $158.00K | $-354.54M | $290.01M | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $617.51M | $21.69M | $20.00K | $-251.96M | $387.25M | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $616.25M | $17.46M | $166.00K | $-161.62M | $472.26M | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $615.74M | $13.87M | $284.00K | $-91.12M | $538.77M | 12 month · $14.19M | (m) | $538.77M |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $100.22M | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $25.00M | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $46.10M | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $34.69M | (m) | (m) | $34.69M |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $321.51M | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $42.13M | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $47.87M | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $16.78M | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $14.45M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |